Propanc Health Group Corporation — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2015, with fiscal 2014 comparative figures. Although the request metadata refers to “2014 Q4,” this is an annual report for FY2015, not a quarterly filing. Amounts are in U.S. dollars unless noted.
Business context
Propanc is a pre-revenue, early-stage biotechnology company developing pro-enzyme cancer treatments, principally PRP, for pancreatic and colorectal solid tumors. The company reported no marketed products and no products in clinical trials as of the fiscal year-end. Its reported research consisted of laboratory and animal studies; the company’s efficacy and safety claims remain unconfirmed in human clinical trials.
Financial results and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1,705,587 | $761,221 |
| Net loss | $3,412,754 | $829,564 |
| Basic and diluted loss per share | $0.02 | $0.01 |
| Net cash used in operating activities | $1,426,479 | $226,442 |
| Cash at year-end | $107,627 | $87,799 |
- Revenue and gross margin are not meaningful because the company had no sales.
- Administration expense rose to $1,567,549 from $742,037, driven mainly by higher professional fees, stock-based expense and capital-raising costs. R&D expense increased to $134,319 from $8,168.
- Interest expense rose to $1,323,902 from $93,147; the filing attributes much of the increase to financing costs, debt premiums and discount accretion. Derivative fair-value expense was $541,981, compared with $16,522 in FY2014. Foreign-currency transaction loss was $244,332, versus $6,959.
- At June 30, 2015, total assets were $627,068 and current liabilities were $3,680,584. Working capital was negative by $3,058,694; stockholders’ deficit was $3,053,516 and accumulated deficit was $20,965,671.
- Convertible notes and related accrued interest, net, totaled $1,794,375; the balance sheet also showed $780,281 of embedded conversion option liabilities and $269,648 of warrant derivative liabilities.
- Financing activities provided $1,282,045 in FY2015, primarily from convertible notes. The company said available cash and committed resources were insufficient to meet obligations over the following 12 months.
Material changes and financing
- Net loss increased by about $2.58 million year over year, while operating cash use increased by about $1.20 million. The company attributed the loss increase principally to higher operating and financing costs, derivative remeasurement and currency losses.
- Common shares outstanding increased from 72,684,767 at June 30, 2014 to 347,442,013 at June 30, 2015, including substantial shares issued upon conversion of debt and for services and settlements. The filing reports 356,624,597 shares outstanding as of September 30, 2015.
- After year-end, the company entered into a $1.2 million note with MG Partners II Limited on September 24, 2015. It matures upon a qualifying subsequent equity financing or by June 24, 2016; if the lender does not proceed with further financing, a one-time $180,000 interest adjustment may apply and the note may convert at a market-discounted price. The related security agreement grants a first-priority interest in company assets, subject to stated removal terms.
Outlook, risks and unusual items
- Management’s stated development plan included animal efficacy work, manufacturing and formal toxicology studies, followed by Phase I testing. The filing estimated approximately $150,000 for animal studies, $600,000 for manufacturing, $650,000 for toxicology and approximately $900,000 for a Phase I study. These were plans and estimates, not completed milestones or assured funding.
- Management targeted Phase IIa proof of concept in about three years and estimated roughly seven years to complete development and obtain approvals. It intended to seek a licensing partner after early clinical milestones and said additional financing would be required.
- The independent auditor issued an unmodified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern. Management’s financing plans were not assured, and the statements contained no adjustments for the outcome of that uncertainty.
- Convertible debt with variable-price conversion features creates potential dilution and derivative-accounting volatility. The filing excluded potentially dilutive securities from loss-per-share calculations as anti-dilutive; it disclosed 335,716,597 shares potentially issuable under convertible notes at year-end.
- JMJ Financial was seeking $25,000 under a convertible note; Propanc was defending the claim and had filed a counterclaim. Management did not expect a material adverse effect, but the matter remained unresolved.
- Management concluded disclosure controls and internal control over financial reporting were ineffective, citing no audit-committee financial expert, limited accounting expertise for complex debt and equity transactions, and inadequate segregation of duties.
- Other notable items included a $375,547 net gain on debt settlements and a $77,470 Australian R&D tax-credit benefit. The company reported that PRP patent protection had been granted or accepted in Australia, New Zealand and South Africa, while other applications remained pending or under review.
Important facts for investors to verify
- Current cash, near-term obligations and the status, funding and conditions of the September 2015 $1.2 million financing.
- Updated debt balances, conversion terms, subsequent conversions and resulting fully diluted share count.
- Whether planned preclinical, manufacturing, toxicology and clinical milestones were funded and completed; human safety and efficacy evidence is not established in this filing.
- Current going-concern assessment and any progress addressing the disclosed material weaknesses in financial reporting controls.
- Status and potential financial exposure of the JMJ litigation, and the scope and enforceability of patent protection in key markets.